List of Excipients in Branded Drug PRETOMANID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	PRETOMANID	pretomanid	49502-476	CELLULOSE, MICROCRYSTALLINE	2029-08-14
Viatris Specialty LLC	PRETOMANID	pretomanid	49502-476	LACTOSE MONOHYDRATE	2029-08-14
Viatris Specialty LLC	PRETOMANID	pretomanid	49502-476	MAGNESIUM STEARATE	2029-08-14
Viatris Specialty LLC	PRETOMANID	pretomanid	49502-476	POVIDONE	2029-08-14

Pretomanid Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Pretomanid is a 200 mg oral tablet used only in combination regimens for drug-resistant tuberculosis. The commercial opportunity is concentrated in formulation optimization, pediatric and dispersible dosage forms, fixed-dose combinations, heat- and humidity-stable products, and qualified excipient supply for high-volume public-health procurement. The current product uses a conventional immediate-release tablet platform, leaving room for differentiated products that improve administration, manufacturing robustness, and global distribution.

What is pretomanid and how is it regulated?

Pretomanid is a nitroimidazole antibacterial developed for pulmonary extensively drug-resistant tuberculosis and treatment-intolerant or nonresponsive multidrug-resistant tuberculosis. The U.S. Food and Drug Administration approved pretomanid tablets on August 14, 2019, under the Limited Population Pathway for Antibacterial and Antifungal Drugs. The product is used with bedaquiline and linezolid in the BPaL regimen, and with bedaquiline, linezolid, and moxifloxacin in BPaLM regimens under applicable treatment guidance.[1,2]

Attribute	Pretomanid
Active ingredient	Pretomanid
Common product strength	200 mg tablet
U.S. product	Dovprela
U.S. NDA	212862
Original U.S. approval	August 14, 2019
Therapeutic area	Drug-resistant pulmonary tuberculosis
Dosage form	Oral immediate-release tablet
Principal commercial party	Viatris, through its Mylan business
Regulatory pathway	Limited Population Pathway
Orphan-drug status	Yes
Primary regimen	BPaL or BPaLM, depending on clinical setting

Pretomanid is a small molecule, not a biologic. Biosimilar regulation therefore does not apply. Future competition would arise through generic abbreviated new drug applications, authorized generics, non-U.S. national applications, or alternative combination products.

What excipients are used in the Dovprela pretomanid tablet?

The U.S. product is a conventional film-coated tablet. Public labeling identifies a formulation built around lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and sodium lauryl sulfate. The film coating contains standard coating components, including hypromellose-based materials and colorants.[3]

Formulation function	Publicly identified or commercially relevant excipient	Strategic role
Diluent	Lactose monohydrate	Tablet mass, compressibility, cost control
Diluent and compression aid	Microcrystalline cellulose	Mechanical strength and direct compression
Superdisintegrant	Croscarmellose sodium	Tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Wetting or dissolution aid	Sodium lauryl sulfate	Improves wetting of a poorly water-soluble active
Film former	Hypromellose	Protection, appearance, swallowability
Opacifier or pigment	Titanium dioxide or equivalent coating pigment	Product identification and light protection

The formulation indicates a practical development objective rather than a complex delivery system: achieve acceptable dissolution and tablet manufacturability at a 200 mg dose while controlling powder flow, lubrication, and disintegration.

Why does pretomanid create an excipient opportunity?

Pretomanid has limited aqueous solubility, making wetting, particle size, solid-state control, and dissolution performance important formulation variables. The commercial opportunity is not necessarily to replace every listed excipient. It is to develop a more robust formulation with fewer processing constraints, broader climatic stability, or easier administration.

The most relevant formulation targets are:

1. Faster and more consistent dissolution.
2. Lower sensitivity to lubricant concentration and mixing time.
3. Improved stability under high temperature and humidity.
4. Lower tablet weight or smaller tablet dimensions.
5. Pediatric administration through dispersible or multiparticulate forms.
6. Compatibility with bedaquiline and linezolid in a fixed-dose combination.
7. Reduced reliance on excipients with supply or regulatory limitations.

Excipient suppliers can pursue these targets through co-processed cellulose, spray-dried lactose, silica-cellulose systems, alternative surfactants, starch-based disintegrants, and high-functionality film-coating systems. The strongest commercial propositions will combine excipient supply with formulation development, process transfer, and regional regulatory support.

What formulation technologies are most suitable for pretomanid?

Direct-compression tablets

Direct compression is the lowest-cost platform for a global tuberculosis product. It minimizes unit operations and is compatible with high-volume manufacturing. The principal development risks are poor flow, segregation, capping, variable disintegration, and sensitivity to magnesium stearate over-lubrication.

A co-processed excipient system combining microcrystalline cellulose and colloidal silicon dioxide could improve flow and compressibility. The commercial value would be highest if the system reduces blending time, supports high-speed compression, and maintains dissolution across different active-particle lots.

Wet granulation

Wet granulation can improve content uniformity and reduce segregation, but it introduces drying, residual-moisture, and stability risks. It may be justified where pretomanid particle properties vary or where the target market uses older compression equipment.

A formulation using povidone or hydroxypropyl cellulose as a binder could improve granule strength. The development burden is higher because granulation liquid, drying temperature, residual moisture, and endpoint control can affect dissolution and impurity formation.

Dry granulation

Roller compaction is potentially attractive for facilities that require better flow without aqueous processing. It also supports continuous or semi-continuous manufacturing. The main risks are ribbon density, over-compaction, loss of tabletability, and slower dissolution after densification.

A dry-granulated formulation could create a process patent opportunity if it achieves equivalent dissolution and stability with a distinct excipient ratio or compaction profile.

Amorphous solid dispersions and lipid systems

These technologies may improve solubility but could be disproportionate to the needs of a 200 mg public-health tablet. They add cost, analytical complexity, and physical-stability risk. They become more commercially relevant for low-dose pediatric formulations, reduced-size tablets, or products that must meet accelerated dissolution specifications with lower surfactant content.

Multiparticulates and dispersible dosage forms

Granules, mini-tablets, and powder-for-suspension products could address pediatric and swallowing limitations. These formats also allow flexible dosing and may support administration through feeding tubes.

The principal technical risks are dose uniformity, segregation, taste masking, moisture uptake, and packaging. A sachet or dispersible tablet may be more commercially practical than a liquid suspension because it avoids preservative systems and reduces cold-chain or reconstitution requirements.

What pediatric pretomanid products could be commercialized?

Pretomanid labeling and clinical use have historically focused on adults and adolescents, while tuberculosis programs continue to require age-appropriate formulations. The pediatric opportunity depends on regulatory acceptance of exposure bridging, weight-band dosing, and combination-regimen development.

Potential products include:

Product concept	Commercial rationale	Key excipient issues
Dispersible tablet	Low water requirement and simplified administration	Rapid dispersion, taste, friability
Oral granules in sachets	Weight-band dosing and distribution flexibility	Moisture protection, dose uniformity
Mini-tablets	Precise pediatric dosing and flexible administration	Compression, coating, swallowability
Powder for suspension	Useful for younger children	Preservatives, sedimentation, reconstitution stability
Pediatric fixed-dose combination	Simplifies BPaL-type treatment	Drug-drug compatibility and dose-ratio control

Taste masking is a major development issue. Pretomanid-containing products may require polymer coating, ion-exchange resins, lipid barriers, or flavor systems. Excipients must be acceptable for pediatric use in the target jurisdictions, including limits on certain surfactants, preservatives, colorants, and sweeteners.

Can pretomanid be developed as a fixed-dose combination?

Yes. Fixed-dose combinations are one of the largest commercial opportunities, although the development is technically and legally more complex than a standalone excipient reformulation.

A BPaL or BPaLM fixed-dose product could reduce pill burden and improve regimen adherence. It would also align with public-health procurement preferences, where simplified regimens reduce dispensing errors and improve logistics.

The principal formulation barriers are:

• Different dose strengths and dose ratios.
• Different dissolution and permeability profiles.
• Potential incompatibility between active ingredients.
• Distinct degradation pathways.
• Large total tablet mass.
• Separate regulatory and intellectual-property positions for bedaquiline, linezolid, and moxifloxacin.
• Need to demonstrate bioequivalence or adequate exposure for each component.

A multilayer tablet, bilayer tablet, co-pack, or sequential blister may be more practical than a single homogeneous tablet. Co-packaging offers a faster commercial route but provides less differentiation than a true fixed-dose combination.

What excipient patents could protect a pretomanid product?

Excipient protection is usually available through formulation and process claims rather than ownership of the excipient itself. A defensible patent strategy could cover:

• Defined pretomanid particle-size distributions.
• Specific ratios of lactose, microcrystalline cellulose, disintegrant, surfactant, and lubricant.
• Co-processed excipient systems.
• Dissolution specifications tied to a formulation architecture.
• Granulation or compaction parameters.
• Moisture-control packaging combined with a stability profile.
• Dispersible, pediatric, or taste-masked formulations.
• Fixed-dose combinations containing pretomanid and one or more companion drugs.
• Manufacturing processes that limit degradation or improve content uniformity.
• Use of a formulation for a defined patient population or weight band.

The strongest claims would connect composition to measurable performance, such as dissolution, impurity control, tablet strength, disintegration, or stability after storage under climatic-zone conditions. Broad claims to ordinary excipient combinations would face greater validity and obviousness risk.

Patent and regulatory distinction

A formulation patent does not automatically create an Orange Book-listed barrier. U.S. listing depends on whether the patent claims the approved drug substance, formulation, composition, or method of use and satisfies FDA listing requirements. A supplier’s excipient patent may remain commercially relevant without being listed against the NDA.

What is the Orange Book and exclusivity status of pretomanid?

The FDA approved Dovprela under NDA 212862. The product’s orphan-drug designation provided seven years of U.S. orphan exclusivity from approval, subject to statutory exceptions. That period would run from August 14, 2019, to August 14, 2026.[1,4]

Exclusivity or barrier	Pretomanid position
U.S. approval	August 14, 2019
Orphan exclusivity	Expected through August 14, 2026
New chemical entity exclusivity	Not the principal commercial protection cited for the product
Patent protection	Depends on listed and unlisted composition, formulation, method, and manufacturing patents
Biosimilar pathway	Not applicable
Generic pathway	ANDA or other national generic route after applicable exclusivity and patent barriers

Patent expiration must be assessed patent by patent. The relevant analysis should separate compound patents, regimen patents, formulation patents, and manufacturing patents. A later-expiring formulation patent may delay a specific product even if the basic compound patent has expired.

Are there Paragraph IV challenges or pretomanid patent litigation?

Publicly documented U.S. market activity has been limited compared with major chronic-care products. The key legal risk is future generic entry after orphan exclusivity and relevant patent barriers expire. Any Paragraph IV filing would depend on Orange Book-listed patents, the timing of ANDA submission, and the scope of the applicant’s proposed label.

Potential challengers would evaluate:

• Whether any listed patent remains enforceable.
• Whether the proposed generic can omit protected method-of-use language.
• Whether a formulation patent can be avoided through a different excipient system.
• Whether the product can be supplied only for non-infringing indications.
• Whether procurement contracts justify litigation costs in a small market.

No biosimilar litigation pathway applies. A formulation competitor could also seek approval outside the United States without relying on the U.S. Orange Book framework.

What generic launch risks exist for pretomanid?

Generic launch risk is substantial after orphan exclusivity if the market remains sufficiently large to support development. The product has several characteristics that reduce and increase generic interest.

Factor	Effect on generic entry
Small patient population	Reduces expected commercial return
Public-health procurement	Can provide volume but compresses price
Simple oral tablet	Lowers technical development barriers
Combination-regimen use	Complicates labeling and clinical positioning
Limited approved indications	Restricts market size
Global TB burden	Supports long-term demand
Formulation simplicity	Increases substitutability
Supply and qualification requirements	Can slow entry in institutional markets

The most likely competitive path is not a large branded-generic market. It is a small number of qualified suppliers competing for government tenders, donor-funded procurement, and national TB-program contracts.

Which companies and institutions influence pretomanid commercialization?

The commercial structure is unusual. TB Alliance developed pretomanid with public and philanthropic support, while Mylan, now part of Viatris, commercialized the U.S. product. The Global Drug Facility and other procurement organizations influence international availability and pricing. National TB programs, the World Health Organization, and donor agencies shape demand through treatment guidance and purchasing decisions.[2,5]

For excipient suppliers, the relevant customer set includes:

• Viatris and other potential finished-dose manufacturers.
• Contract development and manufacturing organizations.
• TB Alliance-linked development partners.
• Generic manufacturers in high-burden countries.
• Public procurement suppliers.
• Packaging and stability-service providers.
• Companies developing bedaquiline-linezolid-moxifloxacin combinations.

Qualification, regulatory documentation, and supply continuity may matter more than premium excipient pricing. Suppliers that can provide multiple pharmacopeial grades, change-control support, and global regulatory files will have an advantage.

What geographic markets offer the strongest commercial opportunity?

Commercial demand is concentrated in countries with multidrug-resistant tuberculosis programs and external procurement support. India, China, Indonesia, the Philippines, South Africa, and several countries in Eastern Europe and Central Asia are strategically relevant because of disease burden, treatment infrastructure, and generic manufacturing capacity.[5]

The product must tolerate distribution and storage conditions consistent with WHO climatic zones. Excipient and packaging strategies should address:

• High humidity and temperature excursions.
• Limited warehouse air conditioning.
• Long procurement lead times.
• Blister or bottle compatibility.
• Serialization and anti-counterfeit requirements.
• Local manufacturing or secondary packaging.
• Stability data for national submissions.

Aluminum-aluminum blister packaging may provide stronger moisture protection than lower-barrier blister systems, but cost and production capability must be considered. High-barrier bottles with desiccants may be appropriate for some markets but add packaging components and handling requirements.

How strong is the pretomanid formulation opportunity?

The formulation opportunity is moderate for adult standalone tablets and stronger for differentiated products. A new adult immediate-release tablet would need a clear advantage in cost, stability, dissolution, manufacturability, or procurement qualification. A pediatric dispersible product or fixed-dose combination offers greater differentiation but requires more clinical and regulatory work.

Opportunity	Technical attractiveness	Commercial attractiveness	IP potential
Adult generic immediate-release tablet	High	Moderate	Low to moderate
Improved direct-compression formulation	High	Moderate	Moderate
Pediatric dispersible tablet	Moderate	High	High
Sachet granules	Moderate	High	Moderate to high
Fixed-dose BPaL product	Low to moderate	High	High
Amorphous solid dispersion	Moderate	Selective	High
Co-processed excipient platform	High	Moderate	Moderate
Heat- and humidity-optimized product	High	High in target markets	Moderate

What licensing and partnership structures are commercially realistic?

The most practical structures are excipient supply agreements, formulation-development partnerships, contract manufacturing arrangements, and co-development deals for pediatric or fixed-dose products. A supplier may contribute a proprietary co-processed excipient or taste-masking system in exchange for development fees, milestone payments, supply rights, or royalties.

For a public-health product, a volume-based price schedule and guaranteed supply capacity may be more valuable than a high unit royalty. Regulatory ownership should be allocated clearly, particularly for formulation dossiers, stability data, process validation, and patent prosecution.

Key Takeaways

• Pretomanid is a 200 mg immediate-release tablet used in drug-resistant tuberculosis regimens.
• The current formulation relies on conventional excipients, including lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and sodium lauryl sulfate.
• The strongest excipient opportunities are pediatric dispersible products, sachet granules, fixed-dose combinations, and formulations optimized for heat and humidity.
• Pretomanid is a small molecule, so generic competition applies; biosimilar competition does not.
• U.S. orphan exclusivity began on August 14, 2019, and is expected to run through August 14, 2026.
• Formulation patents should focus on measurable performance, process conditions, pediatric delivery, stability, or combination products.
• Public-health procurement, supply reliability, and regulatory qualification are central commercial factors.
• A new adult tablet has limited differentiation potential unless it reduces cost, improves stability, or simplifies manufacturing.

FAQs

Is pretomanid poorly soluble?

Pretomanid has limited aqueous solubility, making wetting, particle size, dissolution, and surfactant selection important formulation variables.

What is the best excipient for improving pretomanid dissolution?

No single excipient is universally optimal. Sodium lauryl sulfate, particle engineering, co-processed carriers, and selected wetting agents can improve dissolution, but the final choice depends on stability, dose, manufacturing process, and regulatory acceptability.

Can pretomanid be formulated as an oral suspension?

Yes. An oral suspension or dry powder for reconstitution is technically possible, but taste, sedimentation, dose uniformity, preservative selection, and reconstitution stability must be controlled.

Is a pretomanid fixed-dose combination commercially attractive?

Yes. A fixed-dose BPaL or BPaLM product could reduce pill burden and simplify tuberculosis treatment, but development is constrained by dose ratios, companion-drug patents, bioequivalence, and regulatory requirements.

Do excipient suppliers need their own pretomanid patent?

No. A supplier can commercialize a conventional excipient through supply or development agreements. Patent protection becomes more relevant when the supplier offers a novel co-processed system, pediatric formulation, stability solution, or manufacturing process.

References

1. U.S. Food and Drug Administration. (2019). FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. https://www.fda.gov
2. World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4, treatment: Drug-resistant tuberculosis treatment. World Health Organization.
3. U.S. Food and Drug Administration. (2019). Dovprela (pretomanid) tablets, 200 mg: Prescribing information. Viatris/Mylan.
4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
5. World Health Organization. (2023). Global tuberculosis report 2023. World Health Organization.